Scynexis Fully Integrated Drug Discovery & Development 2011 Overview

SCYNEXIS® Proprietary and Confidential Information

Fully-Integrated Drug Discovery & Development Solut ions

March 28, 2011

SCYNEXIS delivers integrated, efficient and innovative drug discovery and development SOLUTIONS to our global health and pharmaceutical partners. Our record of success is exemplified by the delivery of 11 pre-clinical drug candidates over the last five years. SCYNEXIS also developed the chemical manufacturing process for a customer’s NDA. We are registered with and inspected by both the FDA and DEA.

SCYNEXIS provides Fully-Integrated Contract Research SOLUTIONS including:● Medicinal Chemistry● Lead Optimization● Computational Chemistry● ADMET-PK● Bioanalysis● Process / cGMP Chemistry● Analytical Chemistry


About SCYNEXIS

We provide more than just compounds…We provide you with DRUGS

● Founded in July 2000 in Research Triangle Park, NC● Former Sanofi-Aventis (Rhône-Poulenc) Researchers● 140+ Team Members across the 120,000 ft2 Facilities● Experienced Leadership

◆ Merck, GSK, Sanofi-Aventis, Pfizer, BMS, AstraZeneca, BASF, Lilly, Trimeris, DSM

● Flexible Teams & Unique Risk/Reward Partnering Business◆ FTE’s, Time & Materials, Fixed-Bid Project Work Proposals◆ Profitable Service Business◆ Product and Partnership Upsides

About SCYNEXIS: Founding & Personnel


SCYNEXIS: By the Numbers

● 140+ Employees Across Two Campuses18+ Years of Experience (Average)+60% Ph.D.’s on Chemistry Teams

● 120,000 ft2 facilities in RTP, NC64 Fume HoodsLargest “Chemistry House” in SoutheastLC/MS/MS, HPLC, GC/MS, NMR, DSC


● 100+ Clients Spanning the Globe Virtual/Biotech/Midsize/Top 25MedChem/Process/DMPK

● Strong Financials & Proven Success$29M for 2010Service/Milestones/Royalties>60% CAGR of Revenues11 Preclinical Candidates

Focus on TeamworkIntegrated Project Management &

Weekly Client Updates

Customer Service Excellence>90% Return Rate of Business

Proven Success with Proven Success with SCYNEXISSCYNEXIS

CLIENT

Why SCYNEXIS?

Drug Discovery & Development ExpertiseFully-integrated Research Units (DMPK-MedChem-GMP A PI)

Concept to Marketed Drugs~18 years Experience per FTE

Integrity & ConfidentialityUS Operations, Data Security, Clients own IP

Innovation & CreativityWorld-class Scientists & Proven Track Record

11 PCC’s, multiple IND’s/NDA’s

11 Compounds Nominated 11 Compounds Nominated as Clinical Candidatesas Clinical Candidates


Publicly Disclosed SCYNEXIS Clients

*All publicly disclosed prior to January 2010


SCYNEXIS Process Chemistry

Innovative Drug Pipeline Solutions

Dr. Bob Rodebaugh Director, Process & Analytical [email protected]


The SCYNEXIS Process Team

Process Development FocusedExpert Problem Solvers

Developed Chemical Process for NDA

Experienced LeadershipMerck, GSK, Aventis, Pfizer, BASF, DSM, Lilly

24 Team Members12 Ph.D.’s / 13 Process Chemists /

11 Analytical Chemists

65+ Global Clientele~ 600 Completed Projects

81 in 2008, 85 in 2009, 128 in 2010 $1K - $2 M Range

CLIENT


FDA AuditedPAI – October 2009No Observations

No 483’s

Process Chemistry Expertise

● Broad range of expertise in numerous chemistries including:

◆ Natural Products◆ Carbohydrates◆ Chiral Resolutions◆ Chiral Syntheses◆ Biopolymers & Polymers◆ Cross-coupling Reactions◆ Asymmetric Syntheses

◆ Nucleosides◆ Hydrogenations◆ Heterocyclic Chemistry◆ Pressure Reactions◆ Inorganic Complexes◆ Controlled Substances◆ Stable-labeled Compounds

SCYNEXIS Process Development

● Rapid Turnaround & Efficient Custom SynthesisIntermediates

Reference Standards

Process Impurities

Analog Synthesis

Preparative Chromatography

High Pressure Reactions

● Chemical Development ExpertiseScale-Up of Medicinal Chemistry Routes

Novel Route “Scouting” & Development

Route & Process Optimization

Developed Process for NDA


SCYNEXIS cGMP Manufacturing

● FDA Registered, Inspected● Controlled Access, World-Class Facilities◆ Chemical Development Labs◆ Kilo Scale Lab for non-GMP Scale up◆ GMP Kilo Scale Manufacturing Suite

● Small Scale Commercial Manufacturing◆ PAI October 2009 – No Observations/483s

● <15kg GMP API / <25kg GMP Intermediate

● State of the Art Equipment◆ 25L to 200L Capacity

♦Glass-Lined Stainless Steel ♦Glass Fixed Reactors, -80 to +200 °C ♦ Huber Temperature Controllers

◆ Dedicated Air Handlers◆ Parr 2 Gallon Pressure Reactor◆ Preparative Chromatography


SCYNEXIS Analytical R&D

● Capabilities & Expertise1:1 Ratio of Process : Analytical

GMP/GLP Method Development by Ph.D. Level Scientists

Validation & Stability Studies to ICH GuidelinesImpurity, Degradation Product, Structural Identification

● Key Analytical Instrumentation29 HPLC Systems (Waters/Agilent)

PAD, ELSD, UV-Vis, Fluorescence, UPLC

12 LC/MS & LC/MS/MS Systems

3 GC/MS & GC/FID Headspace/Liquid

GMP 400 & 500 MHz Varian NMR4 Semi-prep Chromatography Systems

DSC/TGA, K-F, TOC, FTIR


SCYNEXIS Quality Systems

GMP Regulatory MissionEnsuring Quality, Purity & Strength

FDA AuditedGeneral Inspection & Pre-Approval Inspection (PAI)

October 2009No Observations, No Form 483s Issued

FDA Regulatory Guidelines21 CFR Parts 210 & 211

GMP FoundationsMaster Validation Plan / SOPs & DocumentControl / Production & Testing Controls /

Project Documentation

GMP

GMP FoundationsQualified Personnel / Qualified Equipment /

Validated Software / Facility Design


SCYNEXIS Medicinal Chemistry


Dr. Mike PeelDirector, Medicinal [email protected]

The SCYNEXIS Medicinal Chemistry Team

Medicinal Chemistry ExpertiseGlobally Recognized Excellence

Experienced LeadershipGSK, AstraZeneca, Sanofi-Aventis,

Pfizer, Lilly, Merck

51 Team Members27 Ph.D’s / Medicinal / Computational

Broad ExpertiseMulti-factorial Optimization,

Parallel Synthesis/Purification, KIT TM

Numerous Therapy Areas

CLIENT

Computational & Cheminformatics SupportHEOS® Data Management & Collaboration Software Suite


Medicinal Chemistry Expertise

● Broad range of expertise in multiple therapeutic areas including:

◆ Natural Product Optimization◆ Antifungals◆ Antivirals◆ Antibacterials◆ Antiparasitics◆ Nuclear Hormones◆ Ion Channels

◆ Oncology◆ Kinases◆ Inflammation◆ Pain◆ Central Nervous System (CNS)◆ Ophthalmology◆ Prodrug Design

SCYNEXIS DMPK & Biology


Dr. Steve WringDirector, DMPK-Tox & [email protected]

The SCYNEXIS DMPK & Biochemistry Team

Broad Areas of ExpertiseFull Support for Discovery - Development

Experienced LeadershipLarge and Small Pharma/Biotech Experience

& Research Investigators

17 Team Members7 Ph.D.’s / 3 MSc / 7 BSc’s

5 LC/MS/MS SystemsCell Culture Suite

Multiple Concurrent ProgramsHits-to-Lead to Lead-Opt

Lead-Opt to Candidate SelectionExploratory Development

CLIENT

Supporting Broad Healthcare InitiativesNeglected Diseases, CNS, Anti-Infectives, Oncology,

Metabolic Diseases, Ophthalmology, Pain, Animal Hea lth


Full Discovery DMPK Function Integrated into MedChe m Decision Process

HEOS® Drug Development Collaboration Tool

Secure web-based portal for real-time data sharing and communication

N

N

O

Ar

NH2

PDF

Third-Party Software

SDFTXT

…


SCYNEXIS Values

IntegrityWe will treat all employees with respect

and ethically conduct business

InnovationWe will continuously generate creative solutions to

both technical and business challenges.

TeamworkWe will work together towards

achieving company goals

SafetySafety concerning employees, customers, public

and the environment. Safety impacts everyaction and decision

SCYNEXIS

QualityWe will deliver superior products and services exceeding our customer’s

expectations


● SCYNEXIS’ Goal◆ Develop Long-Term Relationships via Dedicated Proje ct Resources

Working with SCYNEXIS

Dedicated Project TeamProject LeaderMedicinal ChemistsComputational ChemistsAnalytical & Bioanalytical ChemistsDMPK & ToxicologyBiochemistry & Screening ScientistsProcess Chemists

● Key Attributes◆ Flexibility of the Team◆ Multiple Scientific Disciplines◆ Seamless Functional Transitions◆ 1 – 35 FTE’s

Fully-integrated Research Units

SCYNEXIS is a fully-integrated drug discovery & development company:

◆ Experienced & Highly-Skilled Personnel◆ Proven Record of Success◆ Delivered 11 Preclinical Candidates (IND’s)◆ Integrated Drug Development Solutions◆ State of the Art Facilities◆ FDA & DEA Registered◆ Commercial API Supplier – PAI October 2009◆ Rapid DMPK / Lead-Optimization Studies◆ Dedicated Project Management◆ Desire Long-Term Relationships

SCYNEXIS Summary

Providing more than just compounds… SCYNEXIS provide s you with DRUGS!

Mike Peel, Ph.D. Director, Medicinal Chemistry

[email protected]

Steve Wring, Ph.D. Director, DMPK

[email protected]

Bob Rodebaugh, Ph.D. Director, Process, GMP & Analytical [email protected]

Bryce Chaney, M.B.A.Market Development Manager, Process & Analytical Ch emistry

[email protected]

Terry Marquardt Executive Director, Market [email protected]

SCYNEXIS Inc.3501-C Tricenter Blvd

Durham, NC 27713www.scynexis.com

Contact Information

www.scynexis.com


Thank You!

Documents

Scynexis Fully Integrated Drug Discovery & Development 2011 Overview